Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Aiman Waheed, MBBS
Advertisement
Articles by Aiman Waheed, MBBS
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Advertisement
Latest Updated Articles
Efficacy and Safety of Zolbetuximab in Gastric CancerDecember 6th 2024
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Considering Venlafaxine as Distress Treatment in Breast Cancer
5